Butylene Glycol

Dosage for Butylene Glycol must be highly individualized based on the specific indication and the patient's clinical response.

• For Hyperammonemia (Nitrogen Binding): The typical adult starting dose is 100 mg to 250 mg per kilogram of body weight per day, divided into three or four equal doses. The dose may be titrated upward by a healthcare provider based on serum ammonia levels, up to a maximum of 500 mg/kg/day.
• For Lead Chelation: Standard dosing ranges from 500 mg to 1,000 mg administered intravenously over 4 to 6 hours, once or twice daily, depending on the severity of the lead toxicity and the patient's renal function.
• For Vasodilation: Oral doses typically range from 50 mg to 150 mg three times daily.

Butylene Glycol is approved for use in pediatric populations for the management of urea cycle disorders and lead poisoning.

• Infants and Children: Dosing is strictly weight-based. The common range is 200 mg to 400 mg/kg/day, divided into multiple doses. Because of the risk of metabolic acidosis, pediatric patients must be monitored closely in a hospital setting during the initiation of therapy.
• Neonates: Use in neonates requires extreme caution and is usually reserved for life-threatening hyperammonemia in specialized neonatal intensive care units (NICUs).

Renal Impairment

Since Butylene Glycol and its metabolites are primarily excreted by the kidneys, dosage adjustments are mandatory for patients with impaired renal function.

• Mild to Moderate (CrCl 30-60 mL/min): Reduce the starting dose by 25-50%.
• Severe (CrCl < 30 mL/min): Use is generally contraindicated or requires a 75% dose reduction with continuous monitoring of plasma levels.

Hepatic Impairment

While the liver is involved in the initial metabolism, Butylene Glycol is often used to treat complications of hepatic impairment (like hyperammonemia). However, in cases of severe cirrhosis (Child-Pugh Class C), the rate of conversion to hydroxybutyrate may be slowed, requiring a 20% reduction in dose to prevent accumulation of the parent compound.

Elderly Patients

Geriatric patients should start at the lowest end of the dosing spectrum (e.g., 50-100 mg/kg/day for nitrogen binding) due to the higher prevalence of age-related renal decline and potential for drug-drug interactions.

• Oral Solution: Should be taken with a full glass of water. It can be taken with or without food, but consistency is key. If GI upset occurs, taking it with a small meal may improve tolerance.
• IV Administration: Must be performed by a healthcare professional in a clinical setting. The infusion rate must be strictly controlled to prevent rapid shifts in calcium or pH levels.
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F). Protect from light and moisture. Do not freeze liquid formulations.

If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose to catch up, as this increases the risk of toxicity and metabolic imbalance.

Signs of Butylene Glycol overdose may include:

• Severe nausea and vomiting
• Confusion or lethargy (due to metabolic acidosis)
• Muscle cramps or tetany (due to hypocalcemia from chelation)
• Rapid, shallow breathing
• Hypotension (low blood pressure)

In the event of a suspected overdose, contact a poison control center or seek emergency medical attention immediately. Treatment typically involves supportive care, correction of electrolyte imbalances, and in severe cases, hemodialysis to remove the drug from the bloodstream.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop the medication without medical guidance, as this could lead to a dangerous rebound in ammonia levels or other metabolic complications.

As with any potent metabolic agent, Butylene Glycol can cause various side effects. The most frequently reported include:

• Gastrointestinal Distress: Nausea, vomiting, and abdominal cramping are very common, particularly during the first two weeks of therapy. This is often due to the osmotic effect of the glycol in the gut.
• Flushing and Warmth: Due to its Arteriolar Vasodilator [EPC] properties, many patients experience a sensation of warmth or visible redness in the face, neck, and chest shortly after administration.
• Dizziness: A mild feeling of lightheadedness may occur as blood vessels dilate and blood pressure slightly decreases.
• Diarrhea: High oral doses can lead to osmotic diarrhea, which usually subsides with dose adjustment or over time.

• Headache: Often described as a dull, throbbing sensation, likely related to the drug's vasodilatory effects on cranial blood vessels.
• Metallic Taste: Some patients report a persistent metallic or bitter taste in the mouth (dysgeusia), which is a common side effect of chelating agents.
• Fatigue: A general sense of tiredness or malaise may occur as the body adjusts to changes in nitrogen metabolism.
• Mild Electrolyte Shifts: Small decreases in serum calcium or potassium may be noted on routine blood tests.

• Metabolic Acidosis: An accumulation of acid in the body, characterized by rapid breathing, confusion, and extreme fatigue. This is more common in patients with pre-existing renal disease.
• Hypocalcemic Tetany: Severe muscle spasms or twitching caused by the drug's calcium chelating activity.
• Hypersensitivity Reactions: Skin rash, itching, or hives.
• Tinnitus: Ringing in the ears, which may be a sign of ototoxicity or vascular changes in the inner ear.

> Warning: Stop taking Butylene Glycol and call your doctor immediately if you experience any of the following serious symptoms:

• Anaphylaxis: Signs include swelling of the face, lips, or tongue; difficulty breathing; or a rapid, weak pulse. This is a life-threatening allergic reaction.
• Severe Hypocalcemia: Characterized by seizures, numbness or tingling around the mouth or in the extremities, and cardiac arrhythmias (irregular heartbeat).
• Nephrotoxicity: A sudden decrease in urine output, swelling in the ankles or feet, or blood in the urine, indicating potential kidney damage.
• Profound Hypotension: Fainting, severe dizziness, or a feeling like you might pass out, suggesting an excessive vasodilatory response.
• Hepatotoxicity: Yellowing of the eyes or skin (jaundice), dark urine, or severe right-sided abdominal pain.

Prolonged use of Butylene Glycol, especially at high doses for chronic conditions like urea cycle disorders, may lead to:

• Bone Mineral Density Loss: Chronic calcium chelation can potentially weaken bones over several years if not managed with appropriate supplementation.
• Renal Tubular Changes: Long-term excretion of the drug and its metabolites may cause mild, chronic changes in kidney function that require regular monitoring.
• Vitamin Deficiencies: As a multi-functional binder, it may interfere with the absorption of certain fat-soluble vitamins (A, D, E, and K) over long periods.

At this time, there are no FDA black box warnings for Butylene Glycol. However, this does not diminish the need for strict clinical supervision, particularly regarding its effects on acid-base balance and electrolyte levels.

Report any unusual symptoms or changes in your health to your healthcare provider promptly. Regular blood work is essential to ensure the medication is working effectively and safely.

Butylene Glycol is a potent pharmacological agent that affects multiple systemic pathways, including nitrogen metabolism, vascular tone, and metal ion homeostasis. Patients must be aware that this medication requires frequent clinical monitoring. It is not a simple supplement and should never be shared with others. The risk of metabolic imbalance is significant if the drug is not taken exactly as prescribed.

No FDA black box warnings for Butylene Glycol. While it is generally well-tolerated when used according to established protocols, the potential for rapid metabolic shifts necessitates cautious use in acute care settings.

• Allergic Reactions / Anaphylaxis Risk: While rare, systemic administration of glycols can trigger severe hypersensitivity. Patients with a known allergy to other glycols (such as propylene glycol) should use Butylene Glycol with extreme caution, as cross-sensitivity may occur.
• Metabolic Acidosis: Due to its Acidifying Activity [MoA], Butylene Glycol can increase the acid load in the blood. This is particularly dangerous for patients with respiratory insufficiency, chronic kidney disease, or those prone to ketoacidosis. Regular monitoring of serum bicarbonate and pH is required.
• Electrolyte Depletion: The chelating properties of Butylene Glycol are not entirely specific to lead. It can also bind to essential minerals like calcium, magnesium, and zinc. This can lead to symptomatic deficiencies, including cardiac arrhythmias and muscle dysfunction.
• Renal Toxicity: In high doses or in patients with pre-existing renal impairment, Butylene Glycol may cause tubular necrosis or interstitial nephritis. Kidney function must be assessed before and during treatment.
• Coagulation Issues: Given its Anti-coagulant [EPC] classification, Butylene Glycol may slightly increase the risk of bleeding, especially when combined with other blood thinners. Patients should report any unusual bruising or prolonged bleeding from minor cuts.

Patients taking Butylene Glycol will require regular laboratory testing, typically every 2-4 weeks during the titration phase and every 3 months thereafter:

• Serum Ammonia Levels: To assess the efficacy of nitrogen binding.
• Basic Metabolic Panel (BMP): To monitor electrolytes (calcium, potassium, sodium) and kidney function (BUN, Creatinine).
• Arterial or Venous Blood Gas: To ensure the patient is not developing metabolic acidosis.
• Complete Blood Count (CBC): To check for any signs of anemia or bleeding issues.
• Liver Function Tests (LFTs): To monitor the metabolic capacity of the liver.

Butylene Glycol may cause dizziness, lightheadedness, or blurred vision, particularly during the first few days of treatment or after a dose increase. Patients should not drive, operate heavy machinery, or engage in hazardous activities until they are certain the medication does not impair their ability to perform these tasks safely.

Alcohol consumption should be strictly avoided while taking Butylene Glycol. Alcohol is metabolized by the same enzyme systems (ADH/ALDH) as Butylene Glycol, which can lead to a dangerous buildup of both substances, increasing the risk of toxicity, profound CNS depression, and severe metabolic acidosis.

Butylene Glycol should not be stopped abruptly, especially when used for hyperammonemia. Sudden discontinuation can lead to a rapid, life-threatening spike in ammonia levels (rebound hyperammonemia). If the drug must be stopped, it should be done under a doctor's supervision, often with a gradual tapering of the dose while monitoring blood levels.

> Important: Discuss all your medical conditions, including any history of kidney disease, heart disease, or electrolyte imbalances, with your healthcare provider before starting Butylene Glycol.

Certain medications must never be used in combination with Butylene Glycol due to the risk of life-threatening interactions:

• Ethylene Glycol or Diethylene Glycol: Concurrent exposure can lead to additive nephrotoxicity and overwhelming metabolic acidosis. This is a critical concern in industrial accidents or accidental ingestions.
• Disulfiram (Antabuse): Because Butylene Glycol is metabolized by aldehyde dehydrogenase, disulfiram will block its metabolism, leading to a severe, toxic accumulation of intermediate aldehydes. This can cause extreme vomiting, tachycardia, and chest pain.

• Other Chelating Agents (e.g., EDTA, Penicillamine): Using multiple chelators simultaneously can lead to profound depletion of essential minerals like calcium and zinc, increasing the risk of seizures and heart rhythm problems.
• Potent Diuretics (e.g., Furosemide, Bumetanide): These can exacerbate the electrolyte-wasting effects of Butylene Glycol and increase the risk of dehydration and renal strain.
• Anticoagulants and Antiplatelets (e.g., Warfarin, Clopidogrel, Aspirin): Since Butylene Glycol has inherent anti-coagulant properties, it may enhance the effects of these drugs, significantly increasing the risk of major bleeding events.

• Antihypertensive Medications (e.g., Lisinopril, Amlodipine): The vasodilatory effect of Butylene Glycol may have an additive effect with these drugs, leading to symptomatic hypotension (low blood pressure).
• Corticosteroids: These can cause fluid retention and electrolyte shifts that may counteract the therapeutic goals of Butylene Glycol therapy.
• Insulin and Oral Hypoglycemics: Changes in metabolism and acid-base balance can occasionally affect blood glucose control, requiring more frequent monitoring of blood sugar levels.

• High-Calcium Foods (Dairy): Consuming large amounts of dairy products or calcium-fortified foods near the time of dosing may interfere with the drug's ability to bind lead or other target ions, as it may bind to the dietary calcium instead.
• High-Fat Meals: May delay the absorption of oral Butylene Glycol, though this is generally not clinically significant unless rapid onset is required.
• Caffeine: May worsen the jitteriness or tachycardia sometimes associated with the drug's vasodilatory effects.

• St. John's Wort: May induce the enzymes responsible for Butylene Glycol metabolism, potentially reducing its effectiveness.
• Calcium and Magnesium Supplements: Should be taken at least 2 hours apart from Butylene Glycol to prevent the drug from chelating the supplement rather than the intended target (like lead).
• Garlic, Ginkgo, and Ginseng: These herbs have mild anti-platelet effects and may increase the risk of bruising or bleeding when combined with Butylene Glycol.

Butylene Glycol may interfere with certain laboratory diagnostic tests:

• Serum Creatinine: Some assays may show a falsely elevated creatinine level due to the presence of the glycol in the blood.
• Urinary Ketone Tests: Metabolites of Butylene Glycol (hydroxybutyrate) may cause a false-positive result for ketones in the urine, mimicking ketoacidosis.
• Lead Screening: While it helps remove lead, it can cause a temporary spike in blood lead levels as the metal is mobilized from bone stores into the bloodstream for excretion.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Maintain an up-to-date list of your medications to share with all healthcare providers involved in your care.

Butylene Glycol must NEVER be used in patients with the following conditions:

• Severe Renal Failure (Anuria): In patients who cannot produce urine, the drug and its bound toxins (like lead or ammonia) cannot be excreted. This leads to rapid systemic toxicity and life-threatening metabolic acidosis.
• Known Hypersensitivity: Any previous anaphylactic or severe allergic reaction to Butylene Glycol or related diols is an absolute contraindication.
• Severe Metabolic Acidosis: If a patient is already in a state of uncompensated acidosis (e.g., diabetic ketoacidosis), the acidifying activity of Butylene Glycol will worsen the condition, potentially leading to coma or death.
• Severe Hypocalcemia: Because the drug is a calcium chelator, administering it to someone with dangerously low calcium levels can trigger immediate tetany, seizures, or cardiac arrest.

In these cases, the healthcare provider must carefully weigh the benefits against the risks:

• Moderate Renal Impairment: Requires significant dose reduction and continuous monitoring.
• Congestive Heart Failure (CHF): The vasodilatory effects and potential for electrolyte shifts can destabilize heart rhythm and fluid balance in CHF patients.
• Active Peptic Ulcer Disease: The drug may cause gastrointestinal irritation, which could exacerbate existing ulcers or lead to GI bleeding.
• Dehydration: Patients must be well-hydrated before starting therapy to ensure the kidneys can effectively flush out the chelated complexes.

Patients who have experienced allergic reactions to the following substances should be monitored closely, as they may also react to Butylene Glycol:

• Propylene Glycol: Often found in medications and cosmetics.
• Polyethylene Glycol (PEG): Found in many laxatives and injectable drugs.
• Ethylene Glycol: While primarily a toxin, the chemical structure is similar enough that cross-reactivity in the immune system is possible.

> Important: Your healthcare provider will evaluate your complete medical history, including any allergies and pre-existing conditions, before prescribing Butylene Glycol. Always provide a full and honest medical history.

Butylene Glycol is classified under FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.

• Trimester-Specific Risks: During the first trimester, there is a theoretical risk of interference with metabolic pathways essential for organogenesis. In the third trimester, the drug's vasodilatory and anticoagulant effects could potentially increase the risk of maternal or neonatal hemorrhage.
• Clinical Recommendation: Butylene Glycol should only be used during pregnancy if the potential benefit (e.g., treating life-threatening hyperammonemia) outweighs the potential risk to the fetus. It is not recommended for routine use or minor indications in pregnant women.

It is not known whether Butylene Glycol is excreted in human milk. However, because of its low molecular weight and low protein binding, it is highly likely to pass into breast milk.

• Risks to Infant: A nursing infant could potentially experience electrolyte imbalances or GI distress.
• Management: If Butylene Glycol therapy is necessary for the mother, healthcare providers may recommend temporary discontinuation of breastfeeding or close monitoring of the infant for signs of toxicity.

Butylene Glycol is primarily used in children for the management of inherited urea cycle disorders.

• Growth Effects: Long-term studies on the effect of chronic chelation on bone growth in children are limited. Pediatricians should monitor height, weight, and bone density regularly.
• Dosing: Dosing must be precisely calculated based on body surface area or weight. Small errors in dosing can lead to significant metabolic disturbances in young children.

Elderly patients (65 years and older) are at an increased risk for side effects from Butylene Glycol.

• Fall Risk: The vasodilatory effect can cause orthostatic hypotension (a sudden drop in blood pressure when standing up), significantly increasing the risk of falls and fractures.
• Renal Clearance: Since kidney function naturally declines with age, the half-life of Butylene Glycol is often doubled in the elderly, necessitating lower doses.
• Polypharmacy: Older adults are more likely to be taking interacting medications like diuretics or blood thinners, requiring careful coordination of care.

Renal function is the most critical factor in the safe use of Butylene Glycol.

• GFR-Based Adjustments: Dosage should be adjusted based on the estimated Glomerular Filtration Rate (eGFR).
• Dialysis: Butylene Glycol is dialyzable. For patients on hemodialysis, the drug should be administered after the dialysis session to ensure therapeutic levels are maintained.

In patients with hepatic impairment, particularly those with cirrhosis, the conversion of Butylene Glycol to its metabolites may be impaired. While it is often used to treat the results of liver failure (ammonia), the dose must be carefully titrated to avoid accumulation of the parent glycol, which can be irritating to the central nervous system in high concentrations.

> Important: Special populations require an individualized medical assessment. Always consult with a specialist (such as a nephrologist, hepatologist, or high-risk obstetrician) when using Butylene Glycol in these groups.

Butylene Glycol exerts its therapeutic effects through several distinct molecular pathways. As a Nitrogen Binding Agent, it acts as a precursor to metabolites that conjugate with glutamine and other nitrogenous compounds. This process creates water-soluble molecules that are easily excreted by the renal tubules, effectively bypassing the deficient urea cycle.

In its role as a Lead and Calcium Chelator, the hydroxyl groups on the Butylene Glycol molecule provide electron-rich sites that coordinate with the positively charged metal ions (Pb2+ and Ca2+). This formation of a stable, non-toxic ring structure (chelation) prevents the metal from interacting with cellular enzymes and facilitates its elimination.

As an Arteriolar Vasodilator, it is thought to modulate the activity of nitric oxide synthase or directly interfere with the calcium-induced contraction of vascular smooth muscle, leading to a decrease in systemic vascular resistance.

• Dose-Response: There is a linear relationship between the dose of Butylene Glycol and the reduction in serum ammonia levels. However, the vasodilatory effect often reaches a plateau at higher doses.
• Onset of Action: For nitrogen binding, the onset is typically 2-4 hours after oral administration. For vasodilation, effects may be felt within 30-60 minutes.
• Duration of Effect: The metabolic effects typically last for 6-8 hours, necessitating multiple daily doses.
• Tolerance: There is no evidence of pharmacological tolerance; the drug remains effective over long periods of chronic use.

| Parameter | Value |

|---|---|

| Bioavailability | 88% (Oral) |

| Protein Binding | <15% |

| Half-life | 2 - 5 hours |

| Tmax | 1.5 hours |

| Metabolism | Hepatic (ADH/ALDH) |

| Excretion | Renal (70-85%), Fecal (<5%) |

• Molecular Formula: C4H10O2
• Molecular Weight: 90.12 g/mol
• Solubility: Highly soluble in water and ethanol.
• Structure: A four-carbon chain with hydroxyl groups typically at the 1 and 3 positions (1,3-Butanediol). It is a clear, viscous, odorless liquid in its pure form.

Butylene Glycol is a member of the aliphatic diol class. Within the therapeutic landscape, it is grouped with other nitrogen-scavenging agents like Sodium Phenylbutyrate and other chelating agents like Edetate Calcium Disodium. Its unique combination of EPCs makes it a versatile, albeit specialized, tool in metabolic medicine.